INDIAN FACE
INDIAN EQUITY BENCHMARK
Equity benchmark indices erased morning losses to trade higher in the noon trade as buying is witnessed in Reliance Industries, TCS, HDFC Bank and HUL. The Sensex is trading at 41, 645, higher by 87 points and the Nifty is at 12,244, up 23. Market breadth was positive on the NSE, with 932 advancing stocks as against 734 declines. As per media reports, China has announced new tariff exclusions for some products from the US. Either, M&M, Hero MotoCorp and TCS are among the top gainers, while Yes Bank, Grasim and Vedanta are among top laggards on the NSE.
GLOBAL FACE
Asian Market- Asian markets finished mixed to lower as of the most recent closing prices. Shares in Hong Kong fell as the Hang Seng dropped 0.36%. The Nikkei 225 lost 0.29% while the Shanghai Composite in China closed unchanged.
U.S. Market – North and South American markets finished mixed as of the most recent closing prices. The IPC gained 1.59% and the Bovespa rose 1.51%. The S&P 500 lost 0.04%.
European markets- European markets are mixed. The FTSE 100 is higher by 0.08%, while the DAX is leading the CAC 40 lower. They are down 0.21% and 0.04% respectively.
NIFTY SPOT
MARKET TALKS
Lupin launches Doxercalciferol Injection; stock trades flat
Pharma major Lupin Ltd. announced the launch of Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol® Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials.
Granules India trades lower after co. updates on Metformin Hydrochloride
Granules had conducted a detailed analysis of its Metformin Hydrochloride for N-Nitrosodimethylamine (NDMA). It was concluded from the results that NDMA is absent in Metformin Hydrochloride batches produced by Granules. This was informed to the EU authorities, the company said. Stock view:Granules India Ltd is currently trading at Rs128.10, up by Rs0.1 or 0.08% from its previous closing of Rs128 on the BSE. The scrip opened at Rs127.80 and has touched a high and low of Rs131.45 and Rs126.70 respectively
Clariant has agreed to sell its Masterbatches business for ~USD 1.6bn
Clariant has agreed to sell its entire Masterbatches business to PolyOne. The transaction values the Masterbatches business at USD 1,560 million, representing c. 12.2 times the last twelve months reported EBITDA (ending September 2019) on a cash and debt-free basis. This amount is payable at closing, which is expected by Q3 2020.
Yes Bank slips after India Ratings downgrades long-term issuer rating
Shares of Yes Bank fell after India Ratings downgraded its long-term rating to "A" from "A+". India Ratings and Research (Ind-Ra) has downgraded Yes Bank’s long-term issuer rating to ‘IND A’ from ‘IND A+’ and its short-term issuer rating to ‘IND A1’ from ‘IND A1+’. "The downgrade reflects the inadequate progress as per Ind-Ra's expectations with respect to the quantum and pace of equity infusions, which is critical for providing sufficient cushion for the credit cost impact of the stressed asset pool," India Ratings and Research said.
NAME OF THE STOCK : AVANTIFEED
DATE : 20/12/2019
SEGMENT : CASH
CHART TYPE : Candlestick
EXCHANGE : NSE
TECHNICAL INDICATORS USED : VOLUME.MACD, RSI.
INVESTMENT ADVICE:
CALL CS CALL: BUY AVANTIFEED CASH NR CMP 579 TGT 589 SL 571
RATIONALE FOR ARRIVING INVESTMENT ADVICE :
THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE.
OTHER REASON IF ANY : SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL
CAPITALSTARS CALL US : 9977499927
Derivatives Tips , Intraday Stock Tips , FreeTrading Tips, Sebi Registered advisory
Equity benchmark indices erased morning losses to trade higher in the noon trade as buying is witnessed in Reliance Industries, TCS, HDFC Bank and HUL. The Sensex is trading at 41, 645, higher by 87 points and the Nifty is at 12,244, up 23. Market breadth was positive on the NSE, with 932 advancing stocks as against 734 declines. As per media reports, China has announced new tariff exclusions for some products from the US. Either, M&M, Hero MotoCorp and TCS are among the top gainers, while Yes Bank, Grasim and Vedanta are among top laggards on the NSE.
GLOBAL FACE
Asian Market- Asian markets finished mixed to lower as of the most recent closing prices. Shares in Hong Kong fell as the Hang Seng dropped 0.36%. The Nikkei 225 lost 0.29% while the Shanghai Composite in China closed unchanged.
U.S. Market – North and South American markets finished mixed as of the most recent closing prices. The IPC gained 1.59% and the Bovespa rose 1.51%. The S&P 500 lost 0.04%.
European markets- European markets are mixed. The FTSE 100 is higher by 0.08%, while the DAX is leading the CAC 40 lower. They are down 0.21% and 0.04% respectively.
NIFTY SPOT
MARKET TALKS
Lupin launches Doxercalciferol Injection; stock trades flat
Pharma major Lupin Ltd. announced the launch of Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. Lupin’s Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol® Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials.
Granules India trades lower after co. updates on Metformin Hydrochloride
Granules had conducted a detailed analysis of its Metformin Hydrochloride for N-Nitrosodimethylamine (NDMA). It was concluded from the results that NDMA is absent in Metformin Hydrochloride batches produced by Granules. This was informed to the EU authorities, the company said. Stock view:Granules India Ltd is currently trading at Rs128.10, up by Rs0.1 or 0.08% from its previous closing of Rs128 on the BSE. The scrip opened at Rs127.80 and has touched a high and low of Rs131.45 and Rs126.70 respectively
Clariant has agreed to sell its Masterbatches business for ~USD 1.6bn
Clariant has agreed to sell its entire Masterbatches business to PolyOne. The transaction values the Masterbatches business at USD 1,560 million, representing c. 12.2 times the last twelve months reported EBITDA (ending September 2019) on a cash and debt-free basis. This amount is payable at closing, which is expected by Q3 2020.
Yes Bank slips after India Ratings downgrades long-term issuer rating
Shares of Yes Bank fell after India Ratings downgraded its long-term rating to "A" from "A+". India Ratings and Research (Ind-Ra) has downgraded Yes Bank’s long-term issuer rating to ‘IND A’ from ‘IND A+’ and its short-term issuer rating to ‘IND A1’ from ‘IND A1+’. "The downgrade reflects the inadequate progress as per Ind-Ra's expectations with respect to the quantum and pace of equity infusions, which is critical for providing sufficient cushion for the credit cost impact of the stressed asset pool," India Ratings and Research said.
NAME OF THE STOCK : AVANTIFEED
DATE : 20/12/2019
SEGMENT : CASH
CHART TYPE : Candlestick
EXCHANGE : NSE
TECHNICAL INDICATORS USED : VOLUME.MACD, RSI.
INVESTMENT ADVICE:
CALL CS CALL: BUY AVANTIFEED CASH NR CMP 579 TGT 589 SL 571
RATIONALE FOR ARRIVING INVESTMENT ADVICE :
THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE.
OTHER REASON IF ANY : SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL
DISCLAIMER
The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and upon sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as the only factor while making investment decisions. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets is always subjected to market risk.
CLICK HERE FOR GETTING DETAILS & JOIN OUR BEST ADVISORY -
CAPITALSTARS CALL US : 9977499927
Derivatives Tips , Intraday Stock Tips , FreeTrading Tips, Sebi Registered advisory
0 Comments